Income Taxes (Details) - USD ($) $ in Millions |
12 Months Ended | |
|---|---|---|
Dec. 31, 2021 |
Dec. 31, 2020 |
|
| Income Taxes (Details) [Line Items] | ||
| Deferred tax assets, valuation allowance | $ 62.6 | $ 56.2 |
| Federal income tax purposes, net operating losses | $ 163.0 | |
| Net operating losses, description | NOLs of $120.8 million generated prior to 2018 will begin to expire if unused in 2022. NOLs generated in 2018 and later years of $42.2 million have an indefinite life, but will be limited to 80% of their value if used in a tax year ending after January 1, 2022. | |
| State income tax purposes, net operating losses | $ 87.9 | |
| Federal Research and Development Tax Credits [Member] | ||
| Income Taxes (Details) [Line Items] | ||
| Net operating loss expiration date | The Company has federal research and development tax credits of $2.9 million at December 31, 2021 which will begin to expire in 2034 if unused and orphan drug credits of $11.6 million which will begin to expire in 2028 if unused. | |
| Net operating losses | $ 2.9 | |
| Orphan Drug Credits [Member] | ||
| Income Taxes (Details) [Line Items] | ||
| Net operating losses | $ 11.6 | |